Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases
DOI:
https://doi.org/10.33393/grhta.2024.2892Keywords:
Administrative databases, Cabozantinib, Real-world studies, Renal cell carcinoma, TreatmentAbstract
Background: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited.
Methods: We conducted an analysis based on an integrated administrative database, covering around 6.9 million health-assisted Italian individuals, to explore the use of cabozantinib for RCC. Patients with at least one prescription for cabozantinib during 2017-2020 were searched. These were characterized during all available period (i.e. from 2010 onwards) before the index date and were observed after inclusion.
Results: A total of 113 patients treated with cabozantinib in second or subsequent line were included, and their demographic, clinical and treatment characteristics were described. About half of these RCC patients were aged >65 years (47.8%). Sixty patients (53.1%) were highly adherent to cabozantinib therapy, and the median cabozantinib treatment duration of use was 8.7 months (95% confidence interval: 5.8-11.1). During the first year of follow-up, the average total cost per patient was €32,508.
Conclusions: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases.
Downloads
References
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France 2020: https://gco.iarc.fr/today. Accessed December 2023.
AIOM-AIRTUM. I numeri del cancro in Italia. Il Pensiero Scientifico Editore; 2021.
Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530. https://doi.org/10.1016/j.eururo.2014.10.002 PMID:25449206 DOI: https://doi.org/10.1016/j.eururo.2014.10.002
Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87. https://doi.org/10.14740/wjon1279 PMID:32494314 DOI: https://doi.org/10.14740/wjon1279
Powles T, Albiges L, Bex A, et al; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511-1519. https://doi.org/10.1016/j.annonc.2021.09.014 PMID:34597799 DOI: https://doi.org/10.1016/j.annonc.2021.09.014
Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-1823. https://doi.org/10.1056/NEJMoa1510016 PMID:26406150 DOI: https://doi.org/10.1056/NEJMoa1510016
Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917-927. https://doi.org/10.1016/S1470-2045(16)30107-3 PMID:27279544 DOI: https://doi.org/10.1016/S1470-2045(16)30107-3
Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597. https://doi.org/10.1200/JCO.2016.70.7398 PMID:28199818 DOI: https://doi.org/10.1200/JCO.2016.70.7398
Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-841. https://doi.org/10.1056/NEJMoa2026982 PMID:33657295 DOI: https://doi.org/10.1056/NEJMoa2026982
Corrao G, Cantarutti A. Building reliable evidence from real-world data: needs, methods, cautiousness and recommendations. Pulm Pharmacol Ther. 2018;53:61-67. https://doi.org/10.1016/j.pupt.2018.09.009 PMID:30253238 DOI: https://doi.org/10.1016/j.pupt.2018.09.009
Escudier B, de Zélicourt M, Bourouina R, Nevoret C, Thiery-Vuillemin A. Management and health resource use of patients with metastatic renal cell carcinoma treated with systemic therapy over 2014-2017 in France: a national real-world study. Clin Genitourin Cancer. 2022;20(6):533-542. https://doi.org/10.1016/j.clgc.2022.07.010 PMID:36050262 DOI: https://doi.org/10.1016/j.clgc.2022.07.010
Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Spec Pharm. 2014;20(6):603-610. PMID:24856598 DOI: https://doi.org/10.18553/jmcp.2014.20.6.603
Ronconi G, Dondi L, Piccinni C, et al. Metastatic renal cancer: real-world evidence from a large Italian claims database. Glob Reg Health Technol Assess. 2021;8(1):1-7. https://doi.org/10.33393/grhta.2021.2178 PMID:36627861 DOI: https://doi.org/10.33393/grhta.2021.2178
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. https://doi.org/10.1080/01621459.1958.10501452 DOI: https://doi.org/10.1080/01621459.1958.10501452
Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. Eur J Cancer. 2021;142:102-111. https://doi.org/10.1016/j.ejca.2020.09.030 PMID:33253997 DOI: https://doi.org/10.1016/j.ejca.2020.09.030
Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212-1221. https://doi.org/10.1002/cam4.3717 PMID:33463028 DOI: https://doi.org/10.1002/cam4.3717
Maruzzo M, Pierantoni F, Bortolami A, et al. Real-world treatment with nivolumab or cabozantinib for metastatic renal cell carcinoma (mRCC) in the Veneto region of Italy: results of AMOUR study. Target Oncol. 2022;17(4):467-474. https://doi.org/10.1007/s11523-022-00892-z PMID:35751733 DOI: https://doi.org/10.1007/s11523-022-00892-z
Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Target Oncol. 2020;15(4):495-501. https://doi.org/10.1007/s11523-020-00732-y PMID:32671807 DOI: https://doi.org/10.1007/s11523-020-00732-y
Navani V, Wells JC, Boyne DJ, et al. CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clin Genitourin Cancer. 2023 Feb;21(1):106.e1-106.e8. https://doi.org/10.1016/j.clgc.2022.07.008 PMID:35945133 DOI: https://doi.org/10.1016/j.clgc.2022.07.008
Santoni M, Heng DY, Bracarda S, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers (Basel). 2019;12(1):84. https://doi.org/10.3390/cancers12010084 PMID:31905816 DOI: https://doi.org/10.3390/cancers12010084
Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR. The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. Cancer Manag Res. 2017;9:731-739. https://doi.org/10.2147/CMAR.S148199 PMID:29238223 DOI: https://doi.org/10.2147/CMAR.S148199
Italian Medicine Agency (AIFA). National report on medicines use in Italy – Year 2022 Rome, Italy. 2023. https://www.aifa.gov.it/en/-/l-uso-dei-farmaci-in-italia-rapporto-osmed-2022. Accessed June 2024.
Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1-278. https://doi.org/10.3310/hta22060 PMID:29393024 DOI: https://doi.org/10.3310/hta22060
Stanisic S, Cicchetti A, Porta C, Procopio G, Berto P. Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. Glob Reg Health Technol Assess. 2018;5:1-9 . https://doi.org/10.1177/2284240318790734 DOI: https://doi.org/10.33393/grhta.2018.434
Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA. 2012;307(13):1433-1435. https://doi.org/10.1001/jama.2012.404 PMID:22474208 DOI: https://doi.org/10.1001/jama.2012.404
Gini R, Schuemie MJ, Pasqua A, et al. Monitoring compliance with standards of care for chronic diseases using healthcare administrative databases in Italy: strengths and limitations. PLoS One. 2017;12(12):e0188377. https://doi.org/10.1371/journal.pone.0188377 PMID:29232365 DOI: https://doi.org/10.1371/journal.pone.0188377
Trifirò G, Gini R, Barone-Adesi F, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347-363. https://doi.org/10.1007/s40264-018-0732-5 PMID:30269245 DOI: https://doi.org/10.1007/s40264-018-0732-5
Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-159. https://doi.org/10.5001/omj.2011.38 PMID:22043406 DOI: https://doi.org/10.5001/omj.2011.38
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-06-06
Published 2024-07-03
